Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371118 | 0.96 | MEN1 (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4704955 | 0.91 | MAPT (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3204051 | 0.90 | MEN1 (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL17697673 | 0.89 | ZDHHC7 (0.33) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL888002 | 0.89 | MEN1 (0.49) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL14152956 | 0.88 | HSPD1 (0.35) | MAPTMEN1KMT2AFDPSGPR84 | |
| Acetic Acid SCHEMBL8652586 | 0.88 | HSPD1 (0.35) | MAPTMEN1KMT2AFDPSGPR84 | |
| Acetic Acid SCHEMBL6865045 | 0.88 | MEN1 (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL627516 | 0.88 | MEN1 (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL215134 | 0.86 | ATM (0.47) | MAPTMEN1KMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| US-9861564-B2 | Valeric acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT, LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-9782335-B2 | Malic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160303016-A1 | Valeric Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2445511-B1 | SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS | ELC MAN LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160229791-A1 | Malic Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-08-11 | — | — | US | disclosed |
| EP-2358689-B9 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-9358194-B2 | Succinic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2016-06-07 | — | — | US | disclosed |
| CN-103781632-B | The color laser labeling method of secure file precursor | AGFA-GEVAERT (BE) | 2016-04-27 | — | — | CN | disclosed |
| US-9295621-B2 | Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant | ELC MANAGEMENT LLC (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2006029484-A1 | TOPICAL COMPOSITIONS CONTAINING PHOSPHORYLATED POLYPHENOLS | AJINOMOTO OMNICHEM S.A. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005068420-A1 | UREA AND THIOUREA COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| CN-1620440-A | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMA INC (US) | 2005-05-25 | — | — | CN | disclosed |
| EP-1448537-A4 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040259871-A1 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC | 2004-12-23 | — | — | US | disclosed |
| EP-1448537-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045315-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-5985895-A | 2-naphthamide derivatives and their therapeutic applications | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM (FR) | 1999-11-16 | — | — | US | disclosed |
| US-5872119-A | 2-Naphthamide derivatives and their therapeutic applications | Institut National De La Sante et De La Recherche Medicale--INSERM (FR) | 1999-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | PNLIP, FABP2, GPR119 | MAPT 185/4885MEN1 3991/4885KMT2A 4598/4885 |
| US-20160303016-A1 | Valeric Acid Esters Of Resveratrol And Cosmetic Compositions | CUTA, SUV39H1, RARA | MAPT 1397/4885MEN1 1277/4885KMT2A 1070/4885 |
| US-20040259871-A1 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | GAP43, GRIN2B, GRIN2A | MAPT 626/4885MEN1 4551/4885KMT2A 1378/4885 |
| US-20160229791-A1 | Malic Acid Esters Of Resveratrol And Cosmetic Compositions | ME1, ME2, ME3 | MAPT 1409/4885MEN1 925/4885KMT2A 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.